Clinical trials: Tumor Infiltrating Lymphocytes
Melanoma
TNF in Melanoma Patients Treated With Immunotherapy
This trial is a translational proof-of-concept, open-label, prospective cohort study of 60 patients aiming to identify the clinical markers and/or biomarkers associated with therapeutic response to immune checkpoints inhibitors…
- Trial name
- MELANFα (NCT03348891)
- Testing
- Tumor biopsy specimens and blood samples
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy
This phase I trial tests the effect of Circadian-Optimized Light Therapy (COLT) in conjunction with standard of care tumor-infiltrating lymphocytes (TIL) therapy in treating patients with melanoma that may have spread from where…
- Conditions
- Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma
- Trial name
- NCT07628894
- Testing
- Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Triple Negative Breast Cancer
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients
The PERCEPTION study aims to assess the correlation between blood cell counts (Leucocytes, Neutrophils, Lymphocytes, Platelets, NLR (Neutrophil-to-Lymphocyte Ratio) and PLR (Platelet-to-Lymphocyte Ratio)) and Tumor Infiltrating…
- Trial name
- PERCEPTION (NCT04068623)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centre Jean Perrin
Melanoma
Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
The goal of this proposal is to determine how cannabinoid use affects the tumor immune microenvironment (TME) of melanoma by correlating TILs with reported cannabinoid use and circulating plasma cannabinoids.
- Trial name
- NCT05520294
- Testing
- High-performance liquid chromatography-tandem mass spectrometry assays
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Colorado, Denver
Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle…
- Trial name
- NCT05768347
- Testing
- Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
SCLC, NSCLC
Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab
Marrow infiltrating lymphocytes (MILs™) are a novel method of adoptive cell therapy that provide an activated, polyclonal population of autologous tumor-specific T cells derived from the bone marrow.
- Trial name
- NCT04677361
- Testing
- MILs™ in Combination with Pembrolizumab
- Sponsor
- Fox Chase Cancer Center
Solid Tumor, Gynecological Tumors
Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)
This study is a single-arm, open clinical trial.This trial consists of two phases, dose-escalation and expansion, and the study process is divided into: a screening period, a sampling and production period, a NMA-LD chemotherapy…
- Trial name
- NCT06145802
- Testing
- GT316
- Sponsor
- Grit Biotechnology
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Solid Tumor, Gynecologic Cancer
A Study of GC203 TIL in Advanced Malignant Solid Tumors
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
- Conditions
- Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer
- Trial name
- KUNLUN-001 (NCT06375187)
- Testing
- Engineering Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Cutaneous Melanoma
ITIL-168 in Advanced Melanoma
DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor.
- Trial name
- DELTA-1 (NCT05050006)
- Testing
- ITIL-168
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 29 people
- Sponsor
- Instil Bio
Uveal Melanoma, Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Trial name
- NCT05607095
- Testing
- Lifileucel (LN-144/LN-145)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Estrogen Receptor Positive Tumor
Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor).
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, Menopause, Hormone Antagonist
- Trial name
- ULTIMATE (NCT02997995)
- Testing
- Immune-attractant, Durvalumab, Biopsy
- Where
- 29 sites in France, Spain and 1 more
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
Study of Ipilimumab in the Immune System
Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.
- Trial name
- NCT01715077
- Testing
- Ipilimumab at 3 mg/kg dose
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Non-Small Cell Lung Cancer
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1…
- Trial name
- NCT07444437
- Testing
- LM103 TILs Injection, PD-1 / PD-L1 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Recurrent, Platinum-resistant
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating…
- Conditions
- Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT01883297
- Testing
- Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University Health Network, Toronto
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Tumor Cell, Circulating
Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.
In a prospective study, the influence of adjuvant radiotherapy in patients with non-metastatic breast carcinoma on the epithelial tumor cells (CETCs) circulating in the blood and their immunohistochemical characteristics…
- Trial name
- CETC (NCT04902937)
- Testing
- Adjuvant radiotherapy, neoadjuvant and adjuvant chemotherapy
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University of Jena
Lymphocytes
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors.
- Trial name
- NCT06047977
- Testing
- Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer, Lung Cancer Metastatic
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory lung…
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Lung Cancer Recurrent
- Trial name
- BAH2472 (NCT06538012)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech